Nexstim
14.35 EUR
-1.03 %
5,596 following
NXTMH
First North Finland
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Investor consensus
-1.03 %
-1.37 %
+9.54 %
+71.65 %
+81.65 %
+139.17 %
+241.67 %
+210.65 %
-97.63 %
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read moreMarket cap
103.51M EUR
Turnover
25.49K EUR
P/E (adj.) (25e)
25.4
EV/EBIT (adj.) (25e)
24.7
P/B (25e)
13.13
EV/S (25e)
6.69
Dividend yield-% (25e)
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types
BioStock: Nexstim: from Helsinki to a global brain revolution
Nexstim Receives NBS 6 System Order from New Research Customer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
